FDA-cleared Cleerly ISCHEMIA will assist healthcare professionals in clinical diagnosis and decision making for coronary artery disease
News | Artificial Intelligence
Cleerly ISCHEMIA Software Device Billable With AMA Category I CPT Code for Noninvasive Estimates of Fractional Flow Reserve

February 23, 2024 — Cleerly, the company creating a new standard of care to aid in the diagnosis of heart disease ...

Home February 23, 2024
Home
The DAIC team has learned of the passing of Alain Cribier, MD, FACC, heralded as the man who pioneered the first transcatheter aortic valve replacement (TAVR) in 2002
Feature | Cardiovascular Surgery
In Memoriam: Alain Cribier, MD, FACC, TAVR Pioneer

The DAIC team has learned of the passing of Alain Cribier, MD, FACC, heralded as the man who pioneered the first ...

Home February 23, 2024
Home
Wake Forest University School of Medicine, the academic core of Advocate Health, is expanding another research study to Advocate Christ Medical Center, in Oak Lawn, Illinois, just outside Chicago.
News | Heart Failure
Research Study on Novel Rehab Program for Heart Failure Patients, Led by Wake Forest University School of Medicine, Expands to Advocate Health Site in Chicago

February 22, 2024 — Wake Forest University School of Medicine, the academic core of Advocate Health, is expanding ...

Home February 22, 2024
Home
Ismail El-Hamamsy, MD, PhD, Director of Aortic Surgery for the Mount Sinai Health System and the Mount Sinai Randall B. Griepp, MD Professor in Cardiovascular Surgery at the Icahn School of Medicine at Mount Sinai, was named as the new President of the Heart Valve Society
News | Cardiovascular Business
Ismail El-Hamamsy, MD, PhD, Named President of the Heart Valve Society

February 22, 2024 — Ismail El-Hamamsy, MD, PhD, Director of Aortic Surgery for the Mount Sinai Health System and the ...

Home February 22, 2024
Home
Knowing your family history and getting screened early can be lifesaving
News
Black Families at Increased Risk of Inherited Heart Condition That Can Cause Heart Failure at a Young Age

February 22, 2024 — About 1 in 250 Americans have dilated cardiomyopathy (DCM), a type of inherited heart muscle disease ...

Home February 22, 2024
Home
Athletic Heart will use the Swoop Portable MR Imaging system to provide brain imaging
News | Magnetic Resonance Imaging (MRI)
Hyperfine, Inc. Announces Collaboration with Athletic Heart to Provide Vital Brain Health Imaging for Former Professional Athletes

February 21, 2024 — Hyperfine, Inc., a groundbreaking health technology company that has redefined brain imaging with ...

Home February 21, 2024
Home
Ochsner Children's Hospital, ranked among the top hospitals in the nation for pediatric cardiology and congenital heart surgery, is raising awareness of the need for more pediatric-specific heart devices
News | Pediatric Cardiology
Ochsner Children’s Hospital Advocates to Close the Gap in Pediatric Heart Care

February 21, 2024 — Ochsner Children's Hospital, ranked among the top hospitals in the nation for pediatric cardiology ...

Home February 21, 2024
Home
First of its kind artificial heart valve now approved by FDA for treatment of tricuspid regurgitation.
News | Cardiovascular Clinical Studies
Henry Ford Health Heart Failure Patient First in Michigan to Receive Breakthrough Device

February 21, 2024 — An 80-year-old woman from Frankenmuth, Michigan is the first Henry Ford Health structural heart ...

Home February 21, 2024
Home
Next-generation skin patch-based monitoring platform enables complete freedom of movement for patients in both healthcare and home settings
News | Wearables
X-trodes Receives FDA 510(k) Clearance for Wearable "Skin" Solution that Brings Medical-Grade Electrophysiological Monitoring to the Home

February 20, 2024 — X-trodes, a bio-convergence company bringing wireless monitoring solutions to the home environment ...

Home February 20, 2024
Home
The Medtronic APOLLO Clinical Trial is evaluating the safety and efficacy of an investigative device called the Intrepid Transcatheter Mitral Valve Replacement System (TMVR) for moderate-to-severe or severe symptomatic mitral regurgitation (MR) in patients who may be unsuitable for approved transcatheter repair or surgery.
News | Structural Heart
Hackensack Meridian Jersey Shore University Medical Center Providing State-of-the-Art Medtronic APOLLO Clinical Trial Treating Heart Valve Disease

February 20, 2024 — As New Jersey’s leading provider of high-quality cardiac procedures and diagnostic testing and an ...

Home February 20, 2024
Home
Ultrahigh-spatial-resolution photon-counting detector CT improved assessment of coronary artery disease (CAD), allowing for reclassification to a lower disease category in 54% of patients
News | Computed Tomography (CT)
Photon-Counting CT Improves Coronary Artery Disease Assessment

February 20, 2024 — Ultrahigh-spatial-resolution photon-counting detector CT improved assessment of coronary artery ...

Home February 20, 2024
Home
The study, titled "Targeted Therapy with Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy" (TaRGET), will be led by the research team at PHRI and will involve collaboration with multiple organizations in addition to AMO Pharma including the Hearts in Rhythm Organization (HiRO). 
News | Pharmaceuticals
AMO Pharma Announces Collaboration with Population Health Research Institute to Advance Proof of Concept Clinical Trial to Assess Efficacy of Tideglusib in Treatment of Arrhythmogenic Cardiomyopathy

February 16, 2024 — AMO Pharma Limited, a privately held clinical-stage specialty biopharmaceutical company focusing on ...

Home February 16, 2024
Home
Transformative cardiovascular risk management solutions extend beyond traditional sectors to include federal and state correctional facilities, broker and benefits organizations, and risk bearing providers
News | Artificial Intelligence
Cardio Diagnostics Holdings, Inc. Expands HeartRisk Platform Offering to Diverse Markets in Conjunction with Nationwide Rollout

February 16, 2024 — Cardio Diagnostics Holdings, Inc., an AI-driven precision cardiovascular medicine company, announced ...

Home February 16, 2024
Home
Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a subsidiary of Bayer AG, have announced that the first patient has been randomized in GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II trial of AB-1002, also known as NAN-101, for the treatment of congestive heart failure (CHF).
News | Cardiovascular Clinical Studies
First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure Treatment

February 15, 2024 — Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and ...

Home February 15, 2024
Home
Research findings in a clinical trial led by a professor at the University of Tennessee Health Science Center’s College of Nursing are likely to dramatically change care and improve outcomes for patients suffering from acute stroke.
News | Stroke
ZODIAC Clinical Trial Led by UT Health Science Center Professor Likely to Make Major Impact on Stroke Care

February 15, 2024 — Research findings in a clinical trial led by a professor at the University of Tennessee Health ...

Home February 15, 2024
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now